An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial

Thomas H Wang; Deepak L Bhatt; Keith A A Fox; Steven R Steinhubl; Danielle M Brennan; Werner Hacke; Koon-Hou Mak; Thomas A Pearson; William E Boden; P Gabriel Steg; Marcus D Flather; Gilles Montalescot; Eric J Topol; CHARISMA Investigators

doi:10.1093/eurheartj/ehm274

An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial

Thomas H Wang
, Deepak L Bhatt
, Keith A A Fox
, Steven R Steinhubl
, Danielle M Brennan
, Werner Hacke
, Koon-Hou Mak
, Thomas A Pearson
, William E Boden
, P Gabriel Steg
, Marcus D Flather
, Gilles Montalescot
, Eric J Topol
, CHARISMA Investigators

Research output: Contribution to journal › Article › peer-review

75 Citations (Scopus)

Abstract

To examine the unanticipated, excess mortality observed in patients randomized to clopidogrel and aspirin vs. aspirin alone in the prespecified 'asymptomatic' subgroup of CHARISMA, we investigated whether dual-antiplatelet therapy may be associated with adverse cardiovascular (CV) events in a primary prevention population.

Original language	English
Pages (from-to)	2200-7
Number of pages	8
Journal	European Heart Journal
Volume	28
Issue number	18
DOIs	https://doi.org/10.1093/eurheartj/ehm274
Publication status	Published - Sept 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Aged
Aspirin
Atherosclerosis
Cardiovascular Diseases
Disease-Free Survival
Drug Therapy, Combination
Epidemiologic Methods
Female
Hemorrhage
Humans
Male
Middle Aged
Myocardial Infarction
Platelet Aggregation Inhibitors
Stroke
Ticlopidine

Access to Document

10.1093/eurheartj/ehm274

Cite this

Wang, T. H., Bhatt, D. L., Fox, K. A. A., Steinhubl, S. R., Brennan, D. M., Hacke, W., Mak, K.-H., Pearson, T. A., Boden, W. E., Steg, P. G., Flather, M. D., Montalescot, G., Topol, E. J., & CHARISMA Investigators (2007). An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. European Heart Journal, 28(18), 2200-7. https://doi.org/10.1093/eurheartj/ehm274

@article{a372542d218248ac9f69c692bb028b2a,

title = "An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial",

abstract = "To examine the unanticipated, excess mortality observed in patients randomized to clopidogrel and aspirin vs. aspirin alone in the prespecified 'asymptomatic' subgroup of CHARISMA, we investigated whether dual-antiplatelet therapy may be associated with adverse cardiovascular (CV) events in a primary prevention population.",

keywords = "Aged, Aspirin, Atherosclerosis, Cardiovascular Diseases, Disease-Free Survival, Drug Therapy, Combination, Epidemiologic Methods, Female, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Stroke, Ticlopidine",

author = "Wang, \{Thomas H\} and Bhatt, \{Deepak L\} and Fox, \{Keith A A\} and Steinhubl, \{Steven R\} and Brennan, \{Danielle M\} and Werner Hacke and Koon-Hou Mak and Pearson, \{Thomas A\} and Boden, \{William E\} and Steg, \{P Gabriel\} and Flather, \{Marcus D\} and Gilles Montalescot and Topol, \{Eric J\} and \{CHARISMA Investigators\}",

year = "2007",

month = sep,

doi = "10.1093/eurheartj/ehm274",

language = "English",

volume = "28",

pages = "2200--7",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "18",

}

Wang, TH, Bhatt, DL, Fox, KAA, Steinhubl, SR, Brennan, DM, Hacke, W, Mak, K-H, Pearson, TA, Boden, WE, Steg, PG, Flather, MD, Montalescot, G, Topol, EJ & CHARISMA Investigators 2007, 'An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial', European Heart Journal, vol. 28, no. 18, pp. 2200-7. https://doi.org/10.1093/eurheartj/ehm274

TY - JOUR

T1 - An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial

AU - Wang, Thomas H

AU - Bhatt, Deepak L

AU - Fox, Keith A A

AU - Steinhubl, Steven R

AU - Brennan, Danielle M

AU - Hacke, Werner

AU - Mak, Koon-Hou

AU - Pearson, Thomas A

AU - Boden, William E

AU - Steg, P Gabriel

AU - Flather, Marcus D

AU - Montalescot, Gilles

AU - Topol, Eric J

AU - CHARISMA Investigators

PY - 2007/9

Y1 - 2007/9

N2 - To examine the unanticipated, excess mortality observed in patients randomized to clopidogrel and aspirin vs. aspirin alone in the prespecified 'asymptomatic' subgroup of CHARISMA, we investigated whether dual-antiplatelet therapy may be associated with adverse cardiovascular (CV) events in a primary prevention population.

AB - To examine the unanticipated, excess mortality observed in patients randomized to clopidogrel and aspirin vs. aspirin alone in the prespecified 'asymptomatic' subgroup of CHARISMA, we investigated whether dual-antiplatelet therapy may be associated with adverse cardiovascular (CV) events in a primary prevention population.

KW - Aged

KW - Aspirin

KW - Atherosclerosis

KW - Cardiovascular Diseases

KW - Disease-Free Survival

KW - Drug Therapy, Combination

KW - Epidemiologic Methods

KW - Female

KW - Hemorrhage

KW - Humans

KW - Male

KW - Middle Aged

KW - Myocardial Infarction

KW - Platelet Aggregation Inhibitors

KW - Stroke

KW - Ticlopidine

U2 - 10.1093/eurheartj/ehm274

DO - 10.1093/eurheartj/ehm274

M3 - Article

C2 - 17673448

SN - 0195-668X

VL - 28

SP - 2200

EP - 2207

JO - European Heart Journal

JF - European Heart Journal

IS - 18

ER -